If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

CGEM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.50%

Insider Buying (Last 12 Months): $11,332,672.00

Insider Selling (Last 12 Months): $4,775,189.28

Cullinan Oncology Insider Trading History Chart

Cullinan Oncology Share Price & Price History

^$10.71

▲ +0.2 (1.90%)

As of 03/27/2023 02:03 PM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

Cullinan Oncology Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/25/2022	Jennifer Michaelson	Insider	Sell	4,000	$13.30	$53,200.00	53,031
9/27/2022	Jennifer Michaelson	Insider	Sell	4,000	$12.40	$49,600.00	53,031
8/4/2022	Vision Scs F2	Major Shareholder	Sell	25,989	$14.31	$371,902.59	1,255,963
8/2/2022	Vision Scs F2	Major Shareholder	Sell	4,792	$14.10	$67,567.20	1,301,081
7/25/2022	Jennifer Michaelson	Insider	Sell	8,000	$14.51	$116,080.00	53,031
7/18/2022	Corrine Savill	Insider	Sell	5,042	$15.06	$75,932.52	164,573
7/11/2022	Corrine Savill	Insider	Sell	40,000	$13.33	$533,200.00	169,615
6/23/2022	Bioscience I 2017 Ltd F2	Major Shareholder	Sell	29,631	$13.00	$385,203.00	537,392
6/21/2022	Bioscience I 2017 Ltd F2	Major Shareholder	Sell	22,319	$12.77	$285,013.63	616,976
6/6/2022	Nadim Ahmed	CEO	Buy	8,090	$12.40	$100,316.00	8,090
6/1/2022	Bvf Partners L P/Il	Major Shareholder	Buy	751,396	$11.00	$8,265,356.00	4,058,854
5/16/2022	Vision Scs F2	Major Shareholder	Sell	35,158	$11.23	$394,824.34	1,305,873
5/12/2022	Vision Scs F2	Major Shareholder	Sell	264,072	$9.25	$2,442,666.00	1,460,539
4/1/2022	Bvf Partners L P/Il	Major Shareholder	Buy	276,000	$10.75	$2,967,000.00	301,671
10/18/2021	Jennifer Michaelson	Insider	Sell	4,000	$21.42	$85,680.00
10/15/2021	Jeffrey Trigilio	CFO	Sell	8,000	$25.00	$200,000.00
10/15/2021	Leigh Zawel	Insider	Sell	19,574	$25.00	$489,350.00
10/7/2021	Leigh Zawel	Insider	Sell	1,079	$25.00	$26,975.00
9/20/2021	Jennifer Michaelson	Insider	Sell	4,000	$24.51	$98,040.00
9/15/2021	Ansbert Gadicke	Director	Sell	888	$29.16	$25,894.08
9/15/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	6,425	$29.16	$187,353.00
9/13/2021	Ansbert Gadicke	Director	Sell	497	$29.10	$14,462.70	248,170
9/13/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	3,595	$29.10	$104,614.50	248,170
9/9/2021	Ansbert Gadicke	Director	Sell	1,898	$29.35	$55,706.30
9/9/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	13,727	$29.35	$402,887.45	248,170
9/7/2021	Ansbert Gadicke	Director	Sell	3,465	$29.04	$100,623.60	255,032
9/7/2021	Leigh Zawel	Insider	Sell	28,118	$28.95	$814,016.10
9/7/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	25,067	$29.04	$727,945.68
9/3/2021	Ansbert Gadicke	Director	Sell	1,760	$29.60	$52,096.00	255,032
9/3/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	12,731	$29.60	$376,837.60	255,032
9/1/2021	Ansbert Gadicke	Director	Sell	790	$29.47	$23,281.30	259,975
9/1/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	5,714	$29.47	$168,391.58	259,975
8/30/2021	Ansbert Gadicke	Director	Sell	4,285	$29.30	$125,550.50	264,437
8/30/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	31,001	$29.30	$908,329.30
8/27/2021	Ansbert Gadicke	Director	Sell	1,846	$29.09	$53,700.14	264,437
8/27/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	13,357	$29.09	$388,555.13
8/25/2021	Ansbert Gadicke	Director	Sell	237	$29.09	$6,894.33
8/25/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	1,713	$29.09	$49,831.17
8/23/2021	Ansbert Gadicke	Director	Sell	7,376	$29.11	$214,715.36
8/23/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	53,359	$29.11	$1,553,280.49	273,545
8/11/2021	Ansbert Gadicke	Director	Sell	347	$29.05	$10,080.35	280,921
8/11/2021	Oncology Impact Fund L.P. Ubs	Major Shareholder	Sell	2,510	$29.05	$72,915.50
8/9/2021	Leigh Zawel	Insider	Sell	21,204	$26.57	$563,390.28

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for Cullinan Oncology (NASDAQ:CGEM)

80.85% of Cullinan Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cullinan Oncology Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/23/2023	MetLife Investment Management LLC	16,425	$0.17M	0.0%	-17.4%	0.042%
2/16/2023	Alliancebernstein L.P.	28,200	$0.30M	0.0%	+5.6%	0.062%
2/15/2023	MetLife Investment Management LLC	16,425	$0.17M	0.0%	-17.4%	0.036%
2/15/2023	Tejara Capital Ltd	23,600	$0.25M	0.1%	N/A	0.052%
2/15/2023	Silverarc Capital Management LLC	229,416	$2.42M	0.7%	+2.2%	0.503%
2/15/2023	SVB Financial Group	27,032	$0.29M	0.8%	N/A	0.059%
2/15/2023	Schonfeld Strategic Advisors LLC	34,000	$0.36M	0.0%	N/A	0.075%
2/15/2023	Tang Capital Management LLC	809,231	$8.54M	1.2%	+29.7%	1.774%
2/15/2023	Millennium Management LLC	214,269	$2.26M	0.0%	+43.4%	0.470%
2/15/2023	Morgan Stanley	225,018	$2.37M	0.0%	-21.9%	0.493%
2/15/2023	Norges Bank	101,900	$1.08M	0.0%	N/A	0.223%
2/15/2023	AQR Capital Management LLC	111,360	$1.18M	0.0%	+2.7%	0.244%
2/15/2023	Atom Investors LP	107,193	$1.13M	0.6%	+32.5%	0.235%
2/14/2023	EcoR1 Capital LLC	1,035,038	$10.92M	0.3%	-9.5%	2.269%
2/13/2023	Charles Schwab Investment Management Inc.	220,566	$2.33M	0.0%	+1.4%	0.484%
2/13/2023	Barclays PLC	21,496	$0.23M	0.0%	+139.0%	0.047%
2/13/2023	Renaissance Technologies LLC	307,700	$3.25M	0.0%	+1.8%	0.675%
2/13/2023	Martingale Asset Management L P	41,629	$0.44M	0.0%	+34.2%	0.091%
2/13/2023	Geode Capital Management LLC	557,108	$5.88M	0.0%	+2.9%	1.221%
2/13/2023	American Century Companies Inc.	266,273	$2.81M	0.0%	+237.0%	0.584%
2/10/2023	Bank of America Corp DE	69,829	$0.74M	0.0%	+11.0%	0.153%
2/10/2023	Franklin Resources Inc.	782,126	$8.25M	0.0%	-0.4%	1.715%
2/9/2023	Dimensional Fund Advisors LP	155,678	$1.64M	0.0%	+1,279.6%	0.341%
2/8/2023	UBS Group AG	98,153	$1.04M	0.0%	+7.8%	0.215%
2/8/2023	Swiss National Bank	33,000	$0.35M	0.0%	+6.8%	0.072%
2/7/2023	Fox Run Management L.L.C.	10,412	$0.11M	0.0%	N/A	0.023%
2/2/2023	SG Americas Securities LLC	12,137	$0.13M	0.0%	+8.5%	0.027%
2/2/2023	Nisa Investment Advisors LLC	13,900	$0.15M	0.0%	-19.4%	0.030%
1/12/2023	Assenagon Asset Management S.A.	83,010	$0.88M	0.0%	N/A	0.182%
12/8/2022	Bank of New York Mellon Corp	105,878	$1.36M	0.0%	+14.7%	0.232%
11/28/2022	Birchview Capital LP	25,114	$0.32M	0.2%	-44.3%	0.055%
11/15/2022	Alliancebernstein L.P.	26,700	$0.34M	0.0%	+9.9%	0.059%
11/15/2022	State Street Corp	501,516	$6.43M	0.0%	+5.7%	1.100%
11/15/2022	Tang Capital Management LLC	624,016	$8M	1.0%	+2.4%	1.368%
11/15/2022	Two Sigma Advisers LP	15,000	$0.19M	0.0%	N/A	0.033%
11/15/2022	Trexquant Investment LP	23,657	$0.30M	0.0%	-25.7%	0.052%
11/15/2022	Vanguard Group Inc.	2,765,005	$35.45M	0.0%	+0.7%	6.062%
11/15/2022	Price T Rowe Associates Inc. MD	13,617	$0.18M	0.0%	+15.9%	0.030%
11/15/2022	Marshall Wace LLP	40,576	$0.52M	0.0%	-5.9%	0.089%
11/15/2022	Martingale Asset Management L P	31,016	$0.40M	0.0%	N/A	0.068%
11/15/2022	EcoR1 Capital LLC	1,143,218	$14.66M	0.4%	-2.3%	2.507%
11/15/2022	Bank of New York Mellon Corp	105,878	$1.36M	0.0%	+14.7%	0.232%
11/15/2022	BlackRock Inc.	2,374,825	$30.45M	0.0%	+6.4%	5.207%
11/14/2022	Annandale Capital LLC	10,000	$0.13M	0.0%	N/A	0.022%
11/14/2022	Baupost Group LLC MA	429,646	$5.51M	0.1%	-72.0%	0.942%
11/14/2022	Cubist Systematic Strategies LLC	14,015	$0.18M	0.0%	-86.9%	0.031%
11/14/2022	Renaissance Technologies LLC	302,195	$3.87M	0.0%	+2.9%	0.663%
11/14/2022	Nuveen Asset Management LLC	107,360	$1.38M	0.0%	+1.3%	0.235%
11/14/2022	Rubric Capital Management LP	559,737	$7.18M	0.4%	+88.2%	1.227%
11/14/2022	MetLife Investment Management LLC	19,889	$0.26M	0.0%	+29.2%	0.044%
11/14/2022	Hsbc Holdings PLC	15,283	$0.20M	0.0%	N/A	0.034%
11/10/2022	Dimensional Fund Advisors LP	11,284	$0.15M	0.0%	N/A	0.025%
11/9/2022	Zurcher Kantonalbank Zurich Cantonalbank	3,718	$48K	0.0%	N/A	0.008%
11/8/2022	Atom Investors LP	80,871	$1.04M	0.4%	-16.5%	0.177%
11/8/2022	New York State Common Retirement Fund	23,063	$0.30M	0.0%	+31.2%	0.051%
11/7/2022	Nisa Investment Advisors LLC	17,241	$0.22M	0.0%	+24.0%	0.038%
11/7/2022	Birchview Capital LP	25,114	$0.32M	0.2%	-44.3%	0.055%
11/7/2022	Jump Financial LLC	21,700	$0.28M	0.0%	-48.8%	0.048%
11/3/2022	Barclays PLC	8,994	$0.12M	0.0%	+23.8%	0.020%
11/2/2022	Victory Capital Management Inc.	41,980	$0.54M	0.0%	N/A	0.092%
10/31/2022	SG Americas Securities LLC	11,188	$0.14M	0.0%	-11.3%	0.025%
10/28/2022	Silverarc Capital Management LLC	224,555	$2.88M	1.0%	+5.4%	0.492%
10/26/2022	Allspring Global Investments Holdings LLC	8,765	$0.11M	0.0%	-10.2%	0.019%
8/22/2022	Legal & General Group Plc	5,644	$72K	0.0%	-13.4%	0.012%
8/18/2022	Goldman Sachs Group Inc.	165,309	$2.12M	0.0%	+97.6%	0.362%
8/16/2022	Woodline Partners LP	818,572	$10.49M	0.2%	+72.3%	1.795%
8/15/2022	AQR Capital Management LLC	20,909	$0.27M	0.0%	N/A	0.047%
8/15/2022	State Street Corp	474,428	$6.08M	0.0%	-56.1%	1.059%
8/15/2022	Cubist Systematic Strategies LLC	106,690	$1.37M	0.0%	+587.2%	0.238%
8/15/2022	Millennium Management LLC	321,684	$4.12M	0.0%	+2,959.3%	0.718%
8/13/2022	Renaissance Technologies LLC	293,600	$3.76M	0.0%	N/A	0.656%
8/13/2022	American International Group Inc.	1,237,668	$15.87M	0.1%	+0.1%	2.764%
8/12/2022	Northern Trust Corp	269,277	$3.45M	0.0%	+12.7%	0.601%
8/12/2022	Virtus ETF Advisers LLC	8,620	$0.11M	0.0%	-13.3%	0.019%
8/12/2022	Credit Suisse AG	10,419	$0.13M	0.0%	-15.9%	0.023%
8/12/2022	FMR LLC	214,066	$2.74M	0.0%	-86.9%	0.478%
8/12/2022	Franklin Resources Inc.	779,082	$9.99M	0.0%	+0.2%	1.740%
8/12/2022	Rhumbline Advisers	43,123	$0.55M	0.0%	+34.6%	0.096%
8/11/2022	Trexquant Investment LP	31,851	$0.41M	0.0%	N/A	0.071%
8/11/2022	UBS Group AG	91,776	$1.18M	0.0%	-26.5%	0.205%
8/11/2022	Alps Advisors Inc.	26,565	$0.34M	0.0%	N/A	0.059%
8/11/2022	JPMorgan Chase & Co.	17,995	$0.23M	0.0%	-25.6%	0.040%
8/10/2022	Kennedy Capital Management Inc.	34,347	$0.44M	0.0%	N/A	0.077%
8/9/2022	Swiss National Bank	30,900	$0.40M	0.0%	-14.6%	0.069%
8/3/2022	Nisa Investment Advisors LLC	13,900	$0.18M	0.0%	N/A	0.031%
7/29/2022	SG Americas Securities LLC	12,608	$0.16M	0.0%	N/A	0.028%
7/25/2022	Silverarc Capital Management LLC	213,090	$2.73M	0.8%	N/A	0.476%
6/30/2022	Amalgamated Bank	3,207	$34K	0.0%	N/A	0.007%
6/7/2022	Bank of America Corp DE	45,433	$0.48M	0.0%	+56.4%	0.101%
5/17/2022	Royal Bank of Canada	2,747	$29K	0.0%	-57.9%	0.006%
5/17/2022	Rock Springs Capital Management LP	652,578	$6.83M	0.2%	+1.0%	1.457%
5/16/2022	California State Teachers Retirement System	23,981	$0.25M	0.0%	-10.7%	0.054%
5/16/2022	Goldman Sachs Group Inc.	83,651	$0.88M	0.0%	+4.0%	0.187%
5/16/2022	Deerfield Management Company L.P. Series C	375,585	$3.93M	0.1%	-44.1%	0.839%
5/16/2022	Wellington Management Group LLP	26,396	$0.28M	0.0%	-40.8%	0.059%
5/16/2022	State Street Corp	1,081,537	$11.32M	0.0%	-8.0%	2.415%
5/16/2022	UBS Group AG	124,909	$1.31M	0.0%	+474.5%	0.279%
5/13/2022	Northern Trust Corp	238,943	$2.50M	0.0%	+3.3%	0.534%
5/13/2022	Charles Schwab Investment Management Inc.	178,150	$1.87M	0.0%	+2.3%	0.398%
5/13/2022	Vanguard Group Inc.	2,352,125	$24.63M	0.0%	-0.6%	5.253%

Data available starting January 2016

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $10.71

$10.55

$10.73

50 Day Range

MA: $11.14

$10.43

$11.91

52 Week Range

Now: $10.71

$7.30

$15.89

Volume

79,567 shs

Average Volume

219,188 shs

Market Capitalization

$421.22 million

P/E Ratio

4.52

Dividend Yield

N/A

Beta

0.12

Who are the company insiders with the largest holdings of Cullinan Oncology?: Cullinan Oncology's top insider investors include:
Bvf Partners L P/Il (Major Shareholder)
Vision Scs F2 (Major Shareholder)
Bioscience I 2017 Ltd F2 (Major Shareholder)
Ansbert Gadicke (Director)
Oncology Impact Fund LP Ubs (Major Shareholder)
Corrine Savill (Insider)
Jennifer Michaelson (Insider)
Nadim Ahmed (CEO)
Jeffrey Trigilio (CFO)
Leigh Zawel (Insider)
Learn More about top insider investors at Cullinan Oncology.
Who are the major institutional investors of Cullinan Oncology?: Cullinan Oncology's top institutional investors include:
EcoR1 Capital LLC — 2.27%
Tang Capital Management LLC — 1.77%
Franklin Resources Inc. — 1.71%
Geode Capital Management LLC — 1.22%
Renaissance Technologies LLC — 0.67%
American Century Companies Inc. — 0.58%
Learn More about top institutional investors of Cullinan Oncology stock.
Which institutional investors are selling Cullinan Oncology stock?: During the last quarter, CGEM stock was sold by these institutional investors:
EcoR1 Capital LLC
Morgan Stanley
MetLife Investment Management LLC
MetLife Investment Management LLC
Nisa Investment Advisors LLC
Franklin Resources Inc.
In the last year, company insiders that have sold Cullinan Oncology company stock include:
Bvf Partners L P/Il (Major Shareholder)
Vision Scs F2 (Major Shareholder)
Bioscience I 2017 Ltd F2 (Major Shareholder)
Ansbert Gadicke (Director)
Learn More investors selling Cullinan Oncology stock.
Which institutional investors are buying Cullinan Oncology stock?: During the last quarter, CGEM stock was bought by institutional investors including:
American Century Companies Inc.
Tang Capital Management LLC
Dimensional Fund Advisors LP
Norges Bank
Assenagon Asset Management S.A.
Millennium Management LLC
Schonfeld Strategic Advisors LLC
SVB Financial Group
In the previous year, these company insiders have bought Cullinan Oncology stock:
Bvf Partners L P/Il (Major Shareholder)
Vision Scs F2 (Major Shareholder)
Learn More investors buying Cullinan Oncology stock.

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

CGEM Insider Trading

Cullinan Oncology Insider Trading History Chart

Cullinan Oncology Share Price & Price History

Cullinan Oncology Insider Trading History

SEC Filings (Institutional Ownership Changes) for Cullinan Oncology (NASDAQ:CGEM)

Institutional Buying and Selling by Quarter

Cullinan Oncology Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Cullinan Oncology?

Who are the major institutional investors of Cullinan Oncology?

Which institutional investors are selling Cullinan Oncology stock?

Which institutional investors are buying Cullinan Oncology stock?